Is LDL-C passed its prime? The emerging role of Non-HDL, LDL-P, and ApoB in CHD risk assessment

被引：17
|
作者：
Davidson, Michael H. [1 ]
机构：
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60654 USA
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2008年 / 28卷 / 09期
关键词：
D O I：
10.1161/ATVBAHA.108.172718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1582 / 1583
页数：2
相关论文
共 50 条
  • [31] Prevalence of Statin-Intolerance and Its Impact on LDL-C, Non-HDL-C, and ApoB100 Target Attainment in T2DM
    Hermans, Michel P.
    Camara, Soumaila
    Ahn, Sylvie A.
    Rous-Seau, Michel F.
    DIABETES, 2014, 63 : A160 - A160
  • [32] LDL-C Estimation Equation Performance Characteristics Highlight Value of Preferentially Using Non-HDL Cholesterol or Directly Measured Apolipoprotein B
    Mancini, G. B. John
    Ryomoto, Arnold
    Iatan, Iulia
    Hegele, Robert A.
    CANADIAN JOURNAL OF CARDIOLOGY, 2023, 39 (07) : 963 - 966
  • [33] Low-Density Lipoprotein Particle Number (LDL-P) Distribution in Type 2 Diabetes Who Have Achieved Low Concentrations of Non-HDL Cholesterol (non-HDL-C <80 mg/dL)
    Malave, Hector A.
    Pourfarzib, Ray
    Murthy, Thippeswamy H.
    Burkle, Jamie
    Castro, Manuel E.
    CIRCULATION, 2011, 124 (21)
  • [34] A systematic review and meta-analysis of randomized controlled trials of the effect of barley β-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction
    Ho, H. V. T.
    Sievenpiper, J. L.
    Zurbau, A.
    Mejia, S. Blanco
    Jovanovski, E.
    Au-Yeung, F.
    Jenkins, A. L.
    Vuksan, V.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2016, 70 (11) : 1239 - 1245
  • [35] Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C
    Pencina, Michael J.
    D'Agostino, Ralph B.
    Zdrojewski, Tomasz
    Williams, Ken
    Thanassoulis, George
    Furberg, Curt D.
    Peterson, Eric D.
    Vasan, Ramachandran S.
    Sniderman, Allan D.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (10) : 1321 - 1327
  • [36] RELATIONSHIPS BETWEEN HSCRP REDUCTION AND LDL-C, NON-HDL-C, APOB AND HDL-C IN HYPERLIPIDEMIC PATIENTS TREATED WITH EZETIMIBE/SIMVASTATIN plus EXTENDED-RELEASE NIACIN
    Brown, W. V.
    Fazio, S.
    Guyton, J. R.
    Dong, Q.
    Tomassini, J. E.
    Shah, A.
    Tershakovec, A. M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 14 - 14
  • [37] HIGH LDL-C, NON-HDL-C LEVELS ASSOCIATED WITH HIGHER CVD DEATH RISK, EVEN IN THOSE AT LOW CVD RISK
    Rosenberg, Karen
    AMERICAN JOURNAL OF NURSING, 2018, 118 (12) : 67 - 67
  • [38] Non-HDL-C Is More Accurate Than LDL-C in Identifying Cardiovascular Risk and Is a Significant Therapeutic Target for Treating Dyslipidemia
    Rodriguez, Cynthia G.
    Sink, John, II
    Jacobson, Terry A.
    JOURNAL OF CARDIOVASCULAR NURSING, 2010, 25 (05) : 362 - 362
  • [39] A systematic review and meta-analysis of randomized controlled trials of the effect of barley β-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reductioni-iv
    H V T Ho
    J L Sievenpiper
    A Zurbau
    S Blanco Mejia
    E Jovanovski
    F Au-Yeung
    A L Jenkins
    V Vuksan
    European Journal of Clinical Nutrition, 2016, 70 : 1239 - 1245
  • [40] Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes
    Weinstock, Ruth S.
    Goldberg, Ronald B.
    Guyton, John R.
    Mazzone, Theodore
    Polis, Adam
    Tomassini, Joanne E.
    Lin, Jianxin
    Shah, Arvind
    Tershakovec, Andrew M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (01) : 25 - 35
12345